IBD:诊断活检中发现肉芽肿与克罗恩并发症的高风险相关

2021-05-21 MedSci原创 MedSci原创

克罗恩病(CD)是一种免疫介导的炎症性胃肠道疾病,很难通过临床特征预测疾病的结局。上皮样肉芽肿是组织学诊断的标志之一。

      克罗恩病(CD)是一种免疫介导的炎症性胃肠道疾病,很难通过临床特征预测疾病的结局。上皮样肉芽肿是组织学诊断的标志之一,CD患者发现肉芽肿的患病率范围大概在10%到65%之间。目前尚不清楚在诊断时肉芽肿性炎症是否预示着侵略性的疾病进程。因此,本项研究试图评估CD诊断时的上皮样肉芽肿是否是小儿患者未来疾病严重程度的可靠预测指标。

 

      研究人员将CD诊断时年龄小于21岁的患者纳入本项研究,进行了回顾性队列分析。然后收集了患者的临床信息,包括开始用药的日期以及肛周瘘管或狭窄发展的时间。最后由病理学家审查了患者的活检病理标本。如果在CD诊断后30天内出现肛周瘘管或狭窄,则将患者排除在外。

 

      本项研究最后总共包括了198名患者。诊断时有一半(54%)患有肉芽肿。存在肉芽肿患者的肛周瘘管患病风险增加三倍以上([HR] = 3.24; 95%置信区间CI],1.40–7.48)。免疫调节剂和抗肿瘤坏死因子-α(抗TNF)治疗降低了肛周瘘管的风险。存在肉芽肿性炎症患者对抗TNF治疗产生的反应最为敏感,并降低了肛周瘘管的风险。肉芽肿的存在与狭窄风险无关。免疫调节剂和抗TNF治疗分别使狭窄风险降低96%(HR,= 0.04; 95%CI,0.01–0.22)和94%(HR,= 0.06; 95%CI,0.02–0.20)。

图:肉芽肿与克罗恩病并发症的相关关系

      本项研究证实肉芽肿与肛周瘘管风险增加有关,但与肠道狭窄无关。保留类固醇的疗法似乎可以减少肛周瘘管和狭窄的风险。对于肉芽肿患者,抗TNF-α治疗可大大降低肛周瘘管形成的风险,而免疫调节剂则没有这样的效果。

 

 

原始出处 :

Lindsey S Lawrence. Et al. Granulomas in Diagnostic Biopsies Associated With High Risk of Crohn’s Complications—But May Be Preventable. Inflammatory Bowel Diseases.2021.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-11-15 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-05-26 ms5000000023660064

    积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-05-23 bnurmamat
  5. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-05-23 smlt2008
  6. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1758325, encodeId=6f451e583257b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Nov 15 04:24:45 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862160, encodeId=7bc018621603a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Aug 15 02:24:45 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968786, encodeId=0fad968e86d3, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdf05480664, createdName=ms5000000023660064, createdTime=Wed May 26 23:47:08 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263656, encodeId=b018126365653, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278230, encodeId=e1cf12e8230aa, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344795, encodeId=96441344e956b, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun May 23 14:24:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967728, encodeId=39a196e728d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80a15500741, createdName=yunzhongyan77, createdTime=Sat May 22 14:58:02 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-05-22 yunzhongyan77

    学习了

    0

相关资讯

Clin Gastroenterology H: 克罗恩病患者接受抗肿瘤坏死因子治疗终止后复发的危险因素分析

抗肿瘤坏死因子(TNF)治疗是中重度克罗恩病(CD)患者的诱导和维持治疗的关键疗法。在过去的20年中,CD患者使用抗肿瘤坏死因子已从3%显着增加到41%。

脱脂VS全脂,哪种牛奶更健康?

与脱脂牛奶相比,全脂牛奶显着提高了HDL胆固醇浓度

Clin Gastroenterol H:肛周克罗恩病与疾病不良预后相关

尽管免疫调节剂和生物制剂的利用率更高,但PCD与不良疾病预后相关,尤其是在严重的PCD患者中。

Nature:nod2基因缺陷抑制肠道纤维化和炎症的有效恢复,导致克罗恩病

NOD2基因突变是克罗恩病的危险因素。它们如何导致克罗恩病的许多方面尚不清楚。相关细胞群的发现提出了新的治疗方案。

Clin Trans Gastroenterology:无论表型如何,回肠克罗恩病都表现出相似的透壁纤维化

透壁炎症和粘膜下纤维化是克罗恩病(CD)的重要标志,肠纤维化涉及细胞外基质的积累和间充质细胞的增殖,而炎症是间充质细胞的主要激活剂。

IBD: 体重指数不影响乌司他单抗在克罗恩病中的临床疗效

克罗恩病(CD)是一种慢性发炎性胃肠道(GI)疾病,发病率逐年提高,生物制剂如乌司他单抗的使用大大减少了CD的长期并发症如狭窄,瘘管和手术切除的风险。